Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24420755 | 1.00 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL27054419 | 1.00 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL24420515 | 1.00 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL27056572 | 0.91 | DUT (0.42) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL20369020 | 0.87 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL8840638 | 0.87 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL29716313 | 0.87 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL8840636 | 0.87 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL26181033 | 0.87 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL2056583 | 0.85 | TK1 (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| EP-4240849-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-09-13 | — | — | EP | disclosed |
| CN-116507724-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-20210254067-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-08-19 | — | — | US | disclosed |
| EP-3850099-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | Helmholtz Zentrum München Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3775277-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MultiplexDX, s.r.o. (SK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020070325-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEX DX (SK) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020053186-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-03-19 | — | — | WO | disclosed |
| WO-2017097973-A1 | MODIFIED NUCLEOSIDES | UNIVERSITAET KONSTANZ (DE) | 2017-06-15 | — | — | WO | disclosed |
| US-9605261-B2 | RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end | CHEMGENES CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150218557-A1 | RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END | CHEMGENES CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-8933214-B2 | RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end | CHEMGENES CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TK1 950/4885LMNA 240/4885SMN1; SMN2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.